Etohype Injection contains Etofylline (84.7mg) and Theophylline (25.3mg), two powerful bronchodilator agents used for the management of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
Etofylline works by relaxing bronchial smooth muscles and improving oxygen delivery, while Theophylline enhances diaphragmatic contractility and bronchodilation, together providing effective relief from wheezing, breathlessness, and bronchospasm.
This combination offers rapid onset of action and sustained bronchodilation, making it a preferred choice for acute exacerbations and long-term management in hospital and clinical settings.
Belonging to the respiratory and pulmonology segment, Etohype Injection is in high demand among specialists and healthcare providers. For PCD pharma franchise partners, third-party manufacturers, and exporters, it provides a lucrative B2B opportunity with strong market acceptance and recurring demand.
Common side effects may include nausea, vomiting, headache, tremors, or mild palpitations. Rarely, arrhythmias, hypotension, or severe allergic reactions may occur. Seek immediate medical attention if severe symptoms like chest pain, irregular heartbeat, or difficulty breathing develop.
Etohype Injection is indicated for the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD), and other conditions associated with reversible airway obstruction. It helps relieve wheezing, shortness of breath, and other respiratory symptoms.
Etohype Injection should be administered under the supervision of a healthcare professional. Inform your doctor if you have heart disease, liver or kidney problems, or a history of seizures. Avoid excessive caffeine intake while on treatment.
Store Etohype Injection in a cool, dry place below 25°C, protected from light. Keep the vial tightly closed and out of reach of children.